Eli Lilly Option Alert: Jun 20 $860 Calls at the Bid: 400 vs 1186 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Jun 20 $860 Calls at the Bid: 400 @ $41.4 vs 1186 OI; Earnings 5/1 Before Open Ref=$813.8

Eli Lilly Option Alert: Mar, 2026 $820 Puts Sweep (18) near the Bid: 60 vs 145 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Mar, 2026 $820 Puts Sweep (18) near the Bid: 60 @ $100.404 vs 145 OI; Earnings 5/1 Before Open Ref=$811.0

Eli Lilly Option Alert: Aug 15 $420 Calls at the Ask: 20 vs 2 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Aug 15 $420 Calls at the Ask: 20 @ $399.0 vs 2 OI; Earnings 5/1 Before Open Ref=$809.49

Eli Lilly Option Alert: Dec, 2026 $1180 Puts Sweep (9) near the midpoint: 20 vs 0 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Dec, 2026 $1180 Puts Sweep (9) near the midpoint: 20 @ $379.697 vs 0 OI; Earnings 5/1 Before Open Ref=$811.89

Eli Lilly Option Alert: Dec 19 $1180 Puts Sweep (9) near the midpoint: 20 vs 0 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Dec 19 $1180 Puts Sweep (9) near the midpoint: 20 @ $369.147 vs 0 OI; Earnings 5/1 Before Open Ref=$811.89

Eli Lilly Option Alert: Dec 19 $1120 Puts Sweep (9) near the midpoint: 20 vs 9 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Dec 19 $1120 Puts Sweep (9) near the midpoint: 20 @ $313.067 vs 9 OI; Earnings 5/1 Before Open Ref=$811.26

Eli Lilly Option Alert: Dec, 2026 $1180 Puts Sweep (9) near the Bid: 20 vs 0 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Dec, 2026 $1180 Puts Sweep (9) near the Bid: 20 @ $380.217 vs 0 OI; Earnings 5/1 Before Open Ref=$811.26

Eli Lilly Option Alert: Oct 17 $870 Calls Sweep (15) near the Bid: 71 vs 5 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Oct 17 $870 Calls Sweep (15) near the Bid: 71 @ $71.047 vs 5 OI; Earnings 5/1 Before Open Ref=$819.38

Eli Lilly Option Alert: Jul 18 $540 Calls Sweep (4) near the Bid: 26 vs 9 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Jul 18 $540 Calls Sweep (4) near the Bid: 26 @ $291.0 vs 9 OI; Earnings 5/1 Before Open Ref=$820.99

Eli Lilly Option Alert: Jun 20 $500 Calls Sweep (5) near the Bid: 20 vs 10 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Jun 20 $500 Calls Sweep (5) near the Bid: 20 @ $327.781 vs 10 OI; Earnings 5/1 Before Open Ref=$822.3

Eli Lilly Option Alert: Aug 15 $440 Calls Sweep (6) near the Bid: 28 vs 2 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Aug 15 $440 Calls Sweep (6) near the Bid: 28 @ $390.075 vs 2 OI; Earnings 5/1 Before Open Ref=$822.41

Eli Lilly Option Alert: Dec, 2026 $840 Calls at the Ask: 50 vs 67 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Dec, 2026 $840 Calls at the Ask: 50 @ $155.5 vs 67 OI; Earnings 5/1 Before Open Ref=$825.79

Eli Lilly Option Alert: May 16 $810 Puts at the Ask: 600 vs 265 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: May 16 $810 Puts at the Ask: 600 @ $43.47 vs 265 OI; Earnings 5/1 Before Open Ref=$818.92

Eli Lilly Option Alert: Jan, 2027 $460 Calls at the Bid: 20 vs 20 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Jan, 2027 $460 Calls at the Bid: 20 @ $410.0 vs 20 OI; Earnings 5/1 Before Open Ref=$828.065

Eli Lilly Option Alert: Apr 4 $850 Puts Sweep (13) near the Ask: 500 vs 57 OI; Earnings 5/1 Before Open 

Eli Lilly Option Alert: Apr 4 $850 Puts Sweep (13) near the Ask: 500 @ $13.958 vs 57 OI; Earnings 5/1 Before Open Ref=$854.9

Eli Lilly (NYSE:LLY) Bolsa

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Eli Lilly and Co.

Equities

Government

News

Markets

ABBV

AMGN

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

Trump quiere que las farmacéuticas vuelvan a EE. UU. ¿Cómo afectarán sus aranceles a las acciones del sector?

Trump presiona a farmacéuticas con aranceles para forzar regreso a EE. UU.

US CHINA FLAG Photo by asiandelight on Shutterstock

Tech

Media

AAPL

NVDA

Michael Kratsios toma las riendas de la inteligencia artificial en EE. UU. con un plan estratégico para contener a China.

Michael Kratsios lidera estrategia de IA en EE. UU. para frenar el avance de China

Movers_Stocks

Pre-Market Outlook

Movers

Trading Ideas

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

OLMA

RNAC

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is scheduled to report its quarterly results on Thursday.
The company is likely to report its first-quarter results in line with peers, with some tariff and policy-related commentary during the earnings call, according to Goldman Sachs.
The Eli Lilly Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/67f5483f584c820001291ac6/asad-haider%20">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/67f5483f584c820001291ac6/asad-haider%20">Asad Haider</a> maintained a Buy rating and price target of $888.
The Eli Lilly Thesis: "We expect a decent showing from the tirizepatide franchise (Mounjaro/Zepbound) following the uneven performance featuring misses in the last two quarters," Haider wrote in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Investors are likely to focus on Eli Lilly's obesity franchise, where the company has "continued to solidify its leadership position and frontrunner status in both the GLP-1 injectible market," he added.
Investor focus should also be on the oral obesity pill market, "on the heels of the recent positive ACHIEVE-1 readout for orforglipron int T2D patients," the analyst stated. &nbsp;
The ATTAIN-1 trial is expected in the third quarter and will be "orforglipron's first readout in obesity and hence represents a significant event in the oral obesity space," he wrote.
LLY Price Action: Shares of Eli Lilly had risen by 1.61% to $891.25 at the time of publication on Tuesday.
Read More: <a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449"> </a> • <a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449">Plaintiff Sues Eli Lilly, Johnson &amp; Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications</a>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

Previews

Reiteration

Analyst Ratings

Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) announced a <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">long-term collaboration</a> on Tuesday.
In March, Novo Nordisk introduced&nbsp;NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" rel="noreferrer noopener">cash-paying patients</a>.
Americans can now access NovoCare Pharmacy directly through the Hims &amp; Hers platform. A bundled offering of all dose strengths of Wegovy and a Hims &amp; Hers membership, which includes access to 24/7 care, ongoing clinical support, and <a href="https://www.benzinga.com/pressreleases/25/04/b45063485/hims-hers-and-novo-nordisk-team-up-to-expand-affordable-access-to-care" target="_blank" rel="noreferrer noopener">nutrition guidance</a>.
In March, Novo Nordisk announced updates to the Wegovy&nbsp;savings program, allowing all eligible cash-paying patients to access Wegovy&nbsp;(semaglutide) injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44455562/novo-nordisk-expands-wegovy-499-per-month-offering-to-additional-cash-paying-patients-via-the-wego" rel="noreferrer noopener">cost of&nbsp;$499&nbsp;per month</a>.
Previously, the&nbsp;$499-per-month offer for Wegovy&nbsp;was only available via the recently launched NovoCare&nbsp;Pharmacy.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45019869/novo-nordisk-wins-legal-battle-to-curb-unsafe-knockoff-versions-of-ozempic-wegovy" rel="noreferrer noopener">Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy</a>
On Tuesday, the company said that at a single, unified price starting at $599 per month, individuals may be prescribed Wegovy. The offering is available this week on the Hims &amp; Hers platform.
The companies are also developing a roadmap that combines Novo Nordisk&#8217;s treatments with Hims &amp; Hers&#8217; ability to scale access to quality care, aiming to improve long-term outcomes for more people.
This new offering builds on Hims &amp; Hers&#8217; existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen.
The platform will continue to offer access to other medications, oral kits, protein, nutrition kits, and clinically-backed care plans.
Earlier in April, Hims &amp; Hers Health said it would offer Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound <a href="https://www.benzinga.com/25/04/44593851/hims-hers-health-stock-jumped-tuesday-afternoon-what-happened" target="_blank" rel="noreferrer noopener">through its Telehealth platform</a>.
In a blog post, Hims &amp; Hers announced that it's expanding access to personalized weight loss care.
Hims &amp; Hers said its GLP-1 offering generated over $225 million in <a href="https://www.benzinga.com/general/health-care/25/03/44144092/why-is-hims-hers-health-stock-trading-lower-on-wednesday" target="_blank" rel="noreferrer noopener">revenue in 2024</a>.
Price Action: HIMS stock is up 35.5% at $38.60 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45065830/ups-delivers-mixed-bag-q1-supply-chain-weakness-offset-by-strong-domestic-and-international-growth" target="_blank" rel="noreferrer noopener">UPS Delivers Mixed Bag: Q1 Supply Chain Weakness Offset By Strong Domestic And International Growth</a></li>
</ul>
Photo: Shutterstock

Large Cap

Contracts

General

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform

A personal injury lawsuit was filed seeking damages against Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Kaiser Permanente, alleging their antipsychotic medications Risperdal and Zyprexa, along with generic forms, contributed to the plaintiff <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">developing breast cancer</a>.
The plaintiff claims that the defendants failed to adequately warn about the serious health risks associated with their drugs, which were marketed and sold for a wide range of uses beyond their original psychiatric indications.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report" rel="noreferrer noopener">Trump Administration Considers Lowering US Drug Prices To International Levels: Report</a>
Eli Lilly has manufactured, promoted and distributed Zyprexa since the drug received FDA approval in September 1996.
Both Zyprexa and Risperdal are categorized as second-generation, or atypical, antipsychotics.
Although introduced after 1990, these drugs are not necessarily safer or more effective than first-generation antipsychotics, according to the lawsuit filed last Monday.
The <a href="https://drive.google.com/file/d/1wpMX1c2VQ3m9TgMJiNuvHzSOg_adNiLx/view" target="_blank" rel="noreferrer noopener">complaint</a> further alleges that the drugmakers sought to expand their market by promoting these medications for milder conditions and off-label uses, such as treating attention deficit disorders in children, dementia in the elderly and mood stabilization.
Concerns about the connection between the defendants' drugs and breast cancer reportedly emerged early after their release.
These medications have been found to elevate prolactin levels—a hormone that, when abnormally increased, can result in hyperprolactinemia.
<ul>
<li>This condition is linked to several health complications, including a higher risk of breast cancer. </li>
<li>Despite early clinical trial warnings and subsequent epidemiological studies over the past two decades reinforcing the association, the lawsuit asserts that the defendants neither properly warned consumers nor accurately reported these risks.</li>
</ul>
Instead, the lawsuit claims, the companies actively downplayed the potential dangers by misrepresenting study results and omitting crucial information from drug labels. 
Allegations state that rather than alerting the public, the companies prioritized profits, continuing to promote these costly drugs over older, safer and less expensive alternatives.
As a result, the defendants are accused of profiting billions while exposing consumers to what the lawsuit describes as a potent carcinogen and tumor promoter.
Price Action: LLY stock is down 1.85% at $868.22, and JNJ stock is up 0.21% at $154.90 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45042630/why-is-cancer-drug-developer-revolution-medicines-stock-trading-higher-on-monday" target="_blank" rel="noreferrer noopener">Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?</a></li>
</ul>

Legal

Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$22.00</td>
<td>$44.8K</td>
<td>10.4K</td>
<td>9.6K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$80.00</td>
<td>$29.2K</td>
<td>424</td>
<td>839</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$60.00</td>
<td>$30.9K</td>
<td>8.4K</td>
<td>636</td>
</tr>
<tr>
<td>SMMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$25.00</td>
<td>$34.2K</td>
<td>60</td>
<td>361</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$72.50</td>
<td>$116.2K</td>
<td>52</td>
<td>350</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$66.00</td>
<td>$46.1K</td>
<td>367</td>
<td>320</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$157.50</td>
<td>$60.1K</td>
<td>4</td>
<td>294</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$880.00</td>
<td>$43.9K</td>
<td>2.3K</td>
<td>106</td>
</tr>
<tr>
<td>GEHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$62.00</td>
<td>$27.6K</td>
<td>5</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a put option sweep that happens to be bearish, expiring in 4 day(s) on May 2, 2025. This event was a transfer of 2800 contract(s) at a $22.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $44.8K, with a price of $16.0 per contract. There were 10427 open contracts at this strike prior to today, and today 9611 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 627 day(s) on January 15, 2027. This event was a transfer of 20 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $29.2K, with a price of $1460.0 per contract. There were 424 open contracts at this strike prior to today, and today 839 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bearish sentiment. It expires in 53 day(s) on June 20, 2025. Parties traded 183 contract(s) at a $60.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $30.9K, with a price of $169.0 per contract. There were 8483 open contracts at this strike prior to today, and today 636 contract(s) were bought and sold. 
• For SMMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), we notice a call option trade that happens to be bearish, expiring in 109 day(s) on August 15, 2025. This event was a transfer of 59 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $34.2K, with a price of $580.0 per contract. There were 60 open contracts at this strike prior to today, and today 361 contract(s) were bought and sold. 
• Regarding EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we observe a put option trade with bullish sentiment. It expires in 109 day(s) on August 15, 2025. Parties traded 350 contract(s) at a $72.50 strike. The total cost received by the writing party (or parties) was $116.2K, with a price of $332.0 per contract. There were 52 open contracts at this strike prior to today, and today 350 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option sweep with bullish sentiment. It expires in 18 day(s) on May 16, 2025. Parties traded 278 contract(s) at a $66.00 strike. This particular call needed to be split into 29 different trades to become filled. The total cost received by the writing party (or parties) was $46.1K, with a price of $166.0 per contract. There were 367 open contracts at this strike prior to today, and today 320 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option sweep with bearish sentiment. It expires in 4 day(s) on May 2, 2025. Parties traded 204 contract(s) at a $157.50 strike. This particular put needed to be split into 33 different trades to become filled. The total cost received by the writing party (or parties) was $60.1K, with a price of $295.0 per contract. There were 4 open contracts at this strike prior to today, and today 294 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bearish, expiring in 53 day(s) on June 20, 2025. This event was a transfer of 10 contract(s) at a $880.00 strike. The total cost received by the writing party (or parties) was $43.9K, with a price of $4395.0 per contract. There were 2310 open contracts at this strike prior to today, and today 106 contract(s) were bought and sold. 
• Regarding GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we observe a put option sweep with bullish sentiment. It expires in 18 day(s) on May 16, 2025. Parties traded 240 contract(s) at a $62.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $27.6K, with a price of $115.0 per contract. There were 5 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

GEHC

SMMT

9 Health Care Stocks Whale Activity In Today's Session

WIIM

Eli Lilly shares are trading lower after HSBC downgraded the stock from Buy to Reduce and lowered the price target from $1,150 to $700.

<ul>
<li>Success milestone reached in Scribe and Prevail's ongoing collaboration to accelerate in vivo therapeutics for neurological and neuromuscular diseases using Scribe's CRISPR technology</li>
<li>Companies to jointly present new preclinical data on self-inactivating AAV (siXAAV) technology from their collaboration at the 28th ASGCT Annual Meeting</li>
</ul>
Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced the achievement of a success milestone for one of the targets in its research collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular disorders. The success milestone marks Scribe's second such partnership achievement in 2025.
At the 28th American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting, the companies will have a joint presentation titled "Self-Targeting CRISPR-CasX-Editor AAV Vectors Enable Potent and Controllable On-target Editing in the Murine CNS." The presentation will take place during the poster reception between 5:30 and 7:00 p.m. CT on Thursday, May 15, 2025, at the New Orleans Ernest N. Morial Convention Center.

Scribe Therapeutics And Prevail To Present New Preclinical Data On siXAAV Technology From Collaboration At ASGCT Annual Meeting

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Jeffrey Zekaukas downgraded the rating for Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) from Overweight to Neutral and lowered the price target from $112 to $76. Eastman Chemical shares closed at $75.84 on Friday. <a href="https://www.benzinga.com/quote/EMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Tejas Savant downgraded Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) from Overweight to Equal-Weight and slashed the price target from $25 to $15. Avantor shares closed at $12.93 on Friday. <a href="https://www.benzinga.com/quote/AVTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Rajesh Kumar downgraded the rating for Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) from Buy to Reduce and lowered the price target from $1,150 to $700. Eli Lilly shares closed at $884.54 on Friday. <a href="https://www.benzinga.com/quote/LLY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Javier Martinez downgraded Adecoagro S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) from Equal-Weight to Underweight and cut the price target from $13 to $10. Adecoagro shares closed at $9.92 on Friday. <a href="https://www.benzinga.com/quote/AGRO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying LLY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28085854/image-196-1024x593.png" alt="" class="wp-image-890906" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28085854/image-196-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28085854/image-196-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28085854/image-196-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28085854/image-196.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a> </li>
</ul>
Photo via Shutterstock

AGRO

AVTR

This Eli Lilly Analyst Turns Bearish; Here Are Top 4 Downgrades For Monday

HSBC analyst Rajesh Kumar downgrades Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) from Buy to Reduce and lowers the price target from $1150 to $700.

Downgrades

Price Target

HSBC Downgrades Eli Lilly to Reduce, Lowers Price Target to $700

CNBC&#8217;s Jim Cramer is preparing investors for another action-packed week on Wall Street, packed with earnings reports from major <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">tech players and key economic updates</a>.
On Friday, Cramer emphasized that this week investors should brace for financial updates from Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), alongside critical economic indicators, CNBC <a target="_blank" href="https://www.cnbc.com/2025/04/25/cramers-week-ahead-key-economic-data-and-big-tech-earnings.html" rel="noreferrer noopener">reports</a>.
Cramer warned that the uncertainty around tariff policy remains a major market risk.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/25/04/45012801/3-stocks-to-consider-in-this-outperforming-sector" rel="noreferrer noopener">3 Stocks To Consider In This Outperforming Sector</a>
Without meaningful progress on trade deals, he cautioned that Wall Street might struggle to absorb disappointing earnings, despite the recent market rally.
He described the coming days as &#8220;consequential,&#8221; noting that real trade negotiations must be sorted from political maneuvers to maintain investor confidence. CNBC quotes Cramer, &#8220;We're about to get into the weeds with tariffs.&#8221;
Among industrial names, Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) will post results Monday, with Cramer noting its position at the intersection of tariff discussions and recession concerns.
General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) will report Tuesday, offering potential insight into consumer demand and tariff effects on costs.
Meanwhile, consumer brands Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), and Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) will also share quarterly updates.
Wednesday brings earnings from Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), a stock Cramer watches closely for infrastructure spending clues.
Tech giants Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) will release earnings midweek as well, with advertising trends and AI developments under scrutiny.
On Thursday, attention will turn to Apple and Amazon, with Cramer expecting Apple to pivot towards India and Amazon to highlight its retail and advertising strengths despite tariff pressures.
CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) will post results Thursday, with optimism centered on strong drug sales and insurance performance.
McDonald's Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) is also expected to report healthy growth amid a tough consumer environment.
To close out the week, Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) will report Friday, while the Labor Department&#8217;s nonfarm payrolls data could influence Federal Reserve rate-cut expectations, CNBC notes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/45027471/consumer-tech-news-apr-21-apr-25-microsofts-copilot-gets-a-sleek-new-look-apple-under-fire-for-influence-peddling-in-us-china-trade-more" target="_blank" rel="noreferrer noopener">Consumer Tech News (Apr 21-Apr 25): Microsoft&#8217;s Copilot Gets a Sleek New Look, Apple Under Fire For &#8216;Influence-Peddling&#8217; In US-China Trade &amp; More</a></li>
</ul>
Image: Shutterstock/a katz

Earnings

AMZN

MSFT

SBUX

SPOT

Cramer's Warning: Tariff Chaos Could Derail Tech Earnings Frenzy This Week

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.35% on an annualized basis producing an average annual return of 14.42%. Currently, Eli Lilly has a market capitalization of $797.04 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 20 years ago, it would be worth $15,015.11 today based on a price of $887.40 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745624717_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Live On CNBC Bill Baruch Announces Bought McDonald's And Eli Lilly

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 72 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 43% bearish. Among these notable options, 14 are puts, totaling $1,035,193, and 58 are calls, amounting to $13,672,379.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $500.0 to $1380.0 for Eli Lilly during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale activity within a strike price range from $500.0 to $1380.0 in the last 30 days. 
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745514035_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$134.3</td>
<td>$131.3</td>
<td>$134.3</td>
<td>$1000.00</td>
<td>$671.5K</td>
<td>62</td>
<td>50</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$155.0</td>
<td>$151.0</td>
<td>$151.0</td>
<td>$900.00</td>
<td>$226.5K</td>
<td>140</td>
<td>15</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$44.9</td>
<td>$38.7</td>
<td>$42.0</td>
<td>$600.00</td>
<td>$210.0K</td>
<td>843</td>
<td>50</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$45.9</td>
<td>$44.85</td>
<td>$46.1</td>
<td>$830.00</td>
<td>$138.2K</td>
<td>112</td>
<td>32</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$10.55</td>
<td>$10.15</td>
<td>$10.55</td>
<td>$850.00</td>
<td>$104.4K</td>
<td>1.4K</td>
<td>2.1K</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>With a volume of 1,282,995, the price of LLY is up 3.08% at $854.96. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 7 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $978.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Eli Lilly, which currently sits at a price target of $1124. 
&#x2A; Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Eli Lilly with a target price of $928. 
&#x2A; An analyst from Goldman Sachs has elevated its stance to Buy, setting a new price target at $888. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $975. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Eli Lilly's Options: A Look at What the Big Money is Thinking

Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of&nbsp;Cobenfy&nbsp;(xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia.
In the Phase 3 trial, adjunctive&nbsp;Cobenfy&nbsp;treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical antipsychotic at Week 6, which did not reach the threshold for statistical significance for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44936890/bristol-myers-squibb-announces-topline-results-from-phase-3-arise-trial-evaluating-cobenfy-xanomel" rel="noreferrer noopener">primary endpoint (P = 0.11)</a>.
PANSS is used to assess the severity of positive and negative symptoms. It measures symptoms like hallucinations, delusions, and disorganized thinking, as well as negative symptoms like blunted affect and social withdrawal.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44903741/fda-eases-monitoring-requirements-for-bristol-myers-heart-drug-camzyos-analyst-sees-as-timely-boost-ahead-of-rivals-review" rel="noreferrer noopener">Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach</a>
Preliminary analyses suggest that&nbsp;Cobenfy&nbsp;as an adjunctive treatment to an atypical antipsychotic was associated with improvements in symptoms of schizophrenia compared to placebo plus an atypical antipsychotic for certain patients.
In a post-hoc subgroup analysis, there was a notable difference in response between subjects treated with risperidone as a background therapy compared with the remaining subjects treated with other background antipsychotics (non-risperidone).
Cobenfy's safety and tolerability profile as an adjunctive treatment was consistent with previous monotherapy trials.
Bristol Myers Squibb will complete a full evaluation of the Phase 3 trial data and intends to present detailed results at an upcoming medical conference.
In September 2024, the FDA approved&nbsp;Cobenfy, an oral medication for&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41073709/absence-of-black-box-warning-for-bristol-myers-schizophrenia-treatment-could-enhanc" rel="noreferrer noopener">schizophrenia in adults</a>.
Data from the EMERGENT clinical program supported the FDA approval of Cobenfy. In Phase 3 EMERGENT-2 and EMERGENT-3 trials, Cobenfy met its primary endpoint, demonstrating statistically significant reductions of schizophrenia symptoms compared to placebo from baseline to week five.
William Blair viewed "the ARISE trial as one that could accelerate the uptake of Cobenfy overall, increasing physician confidence in the adjunctive setting ahead of their own personalized approaches."
Even though this setback might lower the chances of strong short-term results, Analyst Matt Phipps still sees a big long-term potential for Cobenfy, with estimated global sales reaching $3.7 billion for schizophrenia.
Bristol is expected to report first-quarter earnings on Thursday, April 24 and it is expected management to provide additional details on the study's impact to the launch curve for Cobenfy and longer-term opportunity.
"The opportunity in Alzheimer's disease psychosis is the next key readout for Cobenfy, where we see significant market opportunity assuming clinical success and a tolerable safety profile," analyst Phipps writes.
In November 2024, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappreciated" rel="noreferrer noopener">two Phase 2 trials</a>.
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the PANSS total score compared to the placebo group at week 6.
Last year, Leerink analyst estimated the potential for peak Cobenfy sales of over $10 billion if it succeeds in additional indications since&nbsp;Eli Lilly And Co's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zyprexa generated $5 billion in peak revenue in 2010 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41913107/bristol-myers-squibbs-14-billion-potential-analyst-upgrades-stock" rel="noreferrer noopener">at much lower prices</a>.
Price Action: BMY stock is down 2.95% at $48.35 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44938762/draftkings-may-trim-2025-forecast-amid-texas-jackpocket-shutdown-says-analyst" target="_blank" rel="noreferrer noopener">DraftKings May Trim 2025 Forecast Amid Texas Jackpocket Shutdown: Analyst</a></li>
</ul>
Photo via Shutterstock

Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

Amid a<a href="https://www.benzinga.com/news/global/25/04/44899617/90-chance-of-recession-due-to-trumps-tariffs-sharp-slowdown-is-coming-economist-says"> challenging political and economic environment</a>, pharmaceutical giant Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) may offer a potential haven in the storm. Fundamentally, the healthcare sector is generally resilient to recessions for a simple reason: when people fall ill, they may need medication and specialized treatment, irrespective of economic conditions. After all, health without wealth doesn't mean much.
In addition, chronic conditions don't pause for bear markets – they occur when they occur, forcing patients to adjust. From a matter of pragmatism, healthcare companies (especially drugmakers like Eli Lilly) can benefit from stable revenue streams, even during downturns. Furthermore, demographic realities, such as the<a href="https://www.benzinga.com/real-estate/24/04/38187933/baby-boomers-dig-in-aging-populations-decision-to-stay-put-adds-to-housing-crunch"> aging U.S. and even global population</a>, translate to healthcare consumption structurally rising.
Indeed, one of the biggest catalysts for LLY stock is its<a href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence"> obesity drug orforglipron</a>. Recently, analysts at Cantor Fitzgerald initiated coverage on Eli Lilly, noting the pharmaceutical giant's potential for dominating the obesity sector. Last week, the company reported topline phase 3 results of the drug for adults with type 2 diabetes. The study's first phase met the primary endpoint of superior blood sugar reduction compared to placebo.
Even better, the enthusiasm hasn't gone unnoticed among the big-money crowd. Recently, traders<a href="https://www.benzinga.com/insights/options/25/04/44931928/9-health-care-stocks-with-whale-alerts-in-todays-session"> bought nearly $77,000 worth of call options</a> with an Aug. 15, 2025, expiration date. As a debit-based transaction, the purchased calls represent "active" speculation as LLY stock must rise beyond the net premium paid for the trade to be profitable.
Nevertheless, not everything about Eli Lilly has resonated with the investing public. Perhaps the biggest concern right now centers on the<a href="https://finance.yahoo.com/quote/lly/key-statistics"> valuation</a>. Presently, LLY stock trades hands at nearly 71 times trailing earnings, which some investors might deem too rich. In addition, LLY trades at more than 52 times book value, a noticeable uptick from years past.
The Direxion ETFs: Another structural concern about engaging LLY stock, whether from the long or short angle, is the share price. At over $800 a pop, LLY has become expensive and thus unwieldy. Even one option contract – which controls 100 shares – now leverages a considerable amount of money, making small trades impractical. That's where financial services provider Direxion offers an alternative pathway.
Speculators have two avenues. First, optimists may consider the Direxion Daily LLY Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELIL#NASDAQ">ELIL</a>), which seeks the daily investment results of 200% of the performance of LLY stock. Second, pessimists may examine the Direxion Daily LLY Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELIS#NASDAQ">ELIS</a>), which tracks 100% of the inverse performance of the namesake security.
Both exchange-traded funds mainly offer convenience for traders, who may desire either a leveraged long position or a short trade without engaging the complexities of the options market. Furthermore, Direxion ETF shares (or units to be more accurate) trade just like any other publicly traded security.
However, the caveat is twofold. Primarily, prospective investors must recognize that leveraged and inverse ETFs can be quite volatile. Also, these specialized ETFs are designed for exposure to last no longer than one day. Beyond that, volatility decay can occur due to the daily compounding problem.
The ELIL ETF: A new financial instrument, the ELIL ETF finds itself down almost 4% since its late-March debut. While choppy, near-term circumstances appear to bode well for the bull fund.
<ul>
<li>LLY stock over the past six years generally features an upward bias, with the chances of a long position held for one week being profitable clocking in at around 58%.</li>
<li>In the past couple of months, LLY has printed five up weeks and five down weeks, with the overall trajectory being positive. This setup generally leads to positive outcomes, possibly boding well for ELIL.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1027" height="625" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23080504/image-1-22.png" alt="" class="wp-image-883987" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23080504/image-1-22.png 1027w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23080504/image-1-22-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23080504/image-1-22-1024x623.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23080504/image-1-22-768x467.png 768w" sizes="(max-width: 1027px) 100vw, 1027px" /></figure>
The ELIS ETF: Appearing in the market at the same time as its bullish counterpart, the ELIS ETF has also encountered a rough start, losing about 3% since its debut.
<ul>
<li>Without adequate baseline data, it's difficult to gauge forward movement. That said, when looking at LLY stock, the printing of a possible bullish flag in the chart warrants caution for ELIS.</li>
<li>Given current trends, it would not be surprising for LLY to drive higher over the next three weeks. However, it's possible that valuation concerns may start to drag on the security, making ELIS potentially intriguing.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1027" height="625" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23080504/image-1-22.png" alt="" class="wp-image-883988" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23080504/image-1-22.png 1027w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23080504/image-1-22-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23080504/image-1-22-1024x623.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23080504/image-1-22-768x467.png 768w" sizes="(max-width: 1027px) 100vw, 1027px" /></figure>
Featured image by <a href="https://pixabay.com/users/rigby40-6395145/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=6826549">Rigby40</a> on <a href="https://pixabay.com/photos/pills-medicines-tablets-dose-rx-6826549/">Pixabay</a>.

Long Ideas

Short Ideas

Technicals

ETFs

ELIL

ELIS

Direxion's Eli Lilly-Focused Bull And Bear Funds Offer Speculative Alternatives

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
What Happened:&nbsp;The Trump Administration is&nbsp;contemplating a policy to align U.S. drug prices with lower rates in other developed countries. The policy is likely to be enforced by the agency responsible for&nbsp;Medicare and Medicaid health programs, reported Reuters&nbsp;citing sources from the pharmaceutical industry.
The sources highlighted this policy as the pharmaceutical industry&#8217;s primary concern, surpassing other government actions under consideration, such as tariffs on imported medicines. One source labeled it as the most significant &#8220;existential&nbsp;threat to the industry and&nbsp;U.S. biosciences innovation.&#8221;
Though the Trump Administration hasn't directly addressed reference pricing, the conservative America First Policy Institute suggested it could be included in Medicare's drug price negotiations.
The industry trade group, PhRMA, has already approached Congress earlier this year regarding this issue, known as international reference pricing. The first source expressed apprehension about the potential upheaval this policy could trigger in the healthcare market, beyond just pharmaceuticals.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/44935195/elizabeth-warren-says-if-trump-illegally-fires-fed-chair-powell-hell-crash-our-markets-cause-more-economic-p" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says, &#8216;If Trump Illegally Fires Fed Chair Powell, He&#8217;ll Crash Our Markets, Cause More Economic Pain To American Families&#8217;</a>
Why It Matters: Under Biden&#8217;s Inflation Reduction Act, the U.S. began negotiating prices for its costliest drugs. However, the negotiated prices for the first 10 drugs remain over twice as high—and sometimes five times higher—than what drugmakers charge in other wealthy nations. During his first term, President Donald Trump&#8216;s attempt to implement an international reference pricing program was halted by a court ruling.
The current report by Reuters comes on the heels of President Trump&#8217;s executive order <a href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">aimed </a>at lowering drug prices and reducing Medicare costs signed earlier this month. The order instructed the Secretary of Health and Human Services to seek guidance for the Medicare Drug Price Negotiation Program for the initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028. 
This potential move is perceived as a major threat to the pharmaceutical industry. Boston University's Rena Conti told Reuters that drugmakers might respond to international reference pricing by raising prices in reference countries, potentially justifying higher U.S. prices and increasing global revenue.
Invesco Pharmaceuticals ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>) and iShares U.S. Pharmaceuticals ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) declined 8.6% and 7.5%, respectively over the past month.
Price Action: During the pre-market session on Wednesday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) gained 2.39%, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) climbed 1.16% and 1.07%, respectively. Meanwhile, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) edged 0.48% higher.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44930938/dogecoin-jumps-7-shiba-inu-up-4-is-a-major-meme-rally-brewing" target="_blank" rel="noreferrer noopener">Dogecoin Jumps 7%, Shiba Inu Up 4%: Is A Major Meme Rally Brewing? &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Administration Considers Lowering US Drug Prices To International Levels: Report

Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced on Tuesday that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals">the next five years.</a>
These investments further strengthen Roche's already significant U.S. footprint, which includes 13 manufacturing and 15 R&amp;D sites across the Pharmaceutical and Diagnostics Divisions.
The investment is expected to <a href="https://www.roche.com/media/releases/med-cor-2025-04-22" target="_blank" rel="noreferrer noopener">create</a> over 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
As part of this investment, Roche will increase its footprint of more than 25,000 employees in 24 sites across eight U.S. states. The investment will include: 
<ul>
<li>Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California.</li>
<li>Gene therapy manufacturing facility in Pennsylvania.</li>
<li>A new 900,000-square-foot manufacturing center to support Roche's expanding portfolio of <a href="https://www.benzinga.com/general/biotech/25/04/44791986/whats-going-on-with-viking-therapeutics-structure-therapeutics-stock-on-monday" target="_blank" rel="noreferrer noopener">next-generation weight loss medicines</a>. The company says the location will be announced.</li>
<li>A new manufacturing facility for continuous glucose monitoring in Indiana.</li>
<li>A new R&amp;D center in Massachusetts for conducting artificial intelligence research and as a hub for new cardiovascular, renal, and metabolism R&amp;D efforts.</li>
<li>Significant expansion and upgrading of existing pharmaceuticals and diagnostics R&amp;D centers in Arizona, Indiana, and California.</li>
</ul>
Once all new and expanded manufacturing capacity comes online, Roche will export more medicines from the U.S. than it imports. The company says its diagnostics division already has an export surplus from the U.S. to other countries.
Earlier this month, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertainties" target="_blank" rel="noreferrer noopener">over the next five years</a>.
The move is part of a broader strategy to ensure that all key Novartis medicines for U.S. patients are produced domestically.
Earlier this year, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>, while Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) plans to double its U.S. drug manufacturing spending from $23 billion to <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">$50 billion within five years</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/04/44929060/boeing-finalizes-10-55-billion-deal-to-divest-jeppesen-and-foreflight-assets" target="_blank" rel="noreferrer noopener">Boeing Finalizes $10.55 Billion Deal To Divest Jeppesen And ForeFlight Assets</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

RHHBY

Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs

Cantor Fitzgerald initiated coverage on Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Monday, citing orforglipron data, which strengthens <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">the case for obesity dominance</a>.
Last week, the U.S. drug giant reported topline Phase 3 results from the ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">diet and exercise alone</a>.
In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C (blood sugar) reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">using the efficacy estimand</a>.
After a choppy second half of 2024, &#8220;Lilly is off to a solid start in &#8217;25,&#8221; Cantor analyst Carter Gould writes. The company reported positive orforglipron ACHIEVE-1 data and improved underlying GLP-1 commercial metrics. 
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44907170/upcoming-pfizer-earnings-call-might-be-focused-on-tariffs-policy-risks-and-obesity-pipeline" rel="noreferrer noopener">Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline</a>
&#8220;&#8230;We view the ACHIEVE-1 data as meaningfully de-risking a 13-16% weight loss profile, and if safety/tolerability holds up, it should leave LLY well-positioned to take share from semaglutide and further grow the market with an oral approach,&#8221; analyst Gould adds.
Cantor writes that Eli Lilly could have an over 85% share of the obesity market by 2029-2030E when the next wave of entrants hits. Cantor initiated with an Overweight rating and a <a target="_blank" href="https://www.benzinga.com/quote/LLY/analyst-ratings" rel="noreferrer noopener">price target of $975</a>.
Eli Lilly&#8217;s first-quarter earnings are in the front row for investors.
The company is scheduled to release the financial performance on 1 May. Analysts expect $4.79 per share earnings with <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $12.93 billion</a>.
Cantor expects modest beats across Mounjaro/Zepbound and that the company will likely reaffirm the FY25 topline guide ($59-61 billion) as a raise is more likely after the second quarter of 2025.
In March, the company announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in India, which is expected to have the second-largest population of overweight or&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">obese people by 2050</a>.
Rival&nbsp;Novo Nordisk A/S&#8217;&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is feeling the pressure as it tries to move up the launch of Wegovy in India to better compete with Lilly.
BofA Securities has also made minor changes to its model for Eli Lilly ahead of Q1 earnings.
BofA analyst Tim Anderson writes that IQVIA recently began including Lilly Direct vials in its TRx (total prescription) data. As for pricing, Eli Lilly expects an overall price decline by the mid-to-high single digits in 2025. While this isn&#8217;t specific to any product, the company suggests that falling prices for its obesity drugs will likely be a major factor.
For 2025/2026, revenues are changed by +1%/+0.4%, and EPS estimates change by +1.9%/-0.7%. No substantial changes to Mounjaro/Zepbound forecasts.
BofA reiterates the Buy rating with a price target of $1,000. &#8220;We continue to like LLY, not &#8220;expensive&#8221; on a PE-to-growth basis, by our math.&#8221;
Price Action: LLY stock is up 0.59% at $822.84 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/04/44928828/devon-energy-unveils-1-billion-annual-optimization-plan-targets-efficiency-gains-by-2026" target="_blank" rel="noreferrer noopener">Devon Energy Unveils $1 Billion Annual Optimization Plan, Targets Efficiency Gains By 2026</a></li>
</ul>
Image: Shutterstock

Initiation

Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$105.00</td>
<td>$35.3K</td>
<td>866</td>
<td align="right">366</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$115.00</td>
<td>$60.0K</td>
<td>332</td>
<td align="right">193</td>
</tr>
<tr>
<td>VSTM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$6.00</td>
<td>$25.6K</td>
<td>5.2K</td>
<td align="right">152</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$445.00</td>
<td>$119.4K</td>
<td>1</td>
<td align="right">98</td>
</tr>
<tr>
<td>PTCT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$49.00</td>
<td>$55.5K</td>
<td>2</td>
<td align="right">67</td>
</tr>
<tr>
<td>SYK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$390.00</td>
<td>$27.3K</td>
<td>137</td>
<td align="right">46</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$135.00</td>
<td>$27.2K</td>
<td>1.7K</td>
<td align="right">26</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$700.00</td>
<td>$76.8K</td>
<td>53</td>
<td align="right">10</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$530.00</td>
<td>$41.0K</td>
<td>119</td>
<td align="right">9</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding CRL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on May 16, 2025. Parties traded 58 contract(s) at a $105.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $35.3K, with a price of $610.0 per contract. There were 866 open contracts at this strike prior to today, and today 366 contract(s) were bought and sold. 
• Regarding THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we observe a put option sweep with neutral sentiment. It expires in 24 day(s) on May 16, 2025. Parties traded 70 contract(s) at a $115.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $60.0K, with a price of $860.0 per contract. There were 332 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding VSTM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), we observe a call option trade with neutral sentiment. It expires in 59 day(s) on June 20, 2025. Parties traded 151 contract(s) at a $6.00 strike. The total cost received by the writing party (or parties) was $25.6K, with a price of $170.0 per contract. There were 5217 open contracts at this strike prior to today, and today 152 contract(s) were bought and sold. 
• Regarding ISRG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), we observe a call option trade with bearish sentiment. It expires in 87 day(s) on July 18, 2025. Parties traded 20 contract(s) at a $445.00 strike. The total cost received by the writing party (or parties) was $119.4K, with a price of $5972.0 per contract. There were 1 open contracts at this strike prior to today, and today 98 contract(s) were bought and sold. 
• For PTCT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>), we notice a call option sweep that happens to be bearish, expiring in 241 day(s) on December 19, 2025. This event was a transfer of 50 contract(s) at a $49.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $55.5K, with a price of $1110.0 per contract. There were 2 open contracts at this strike prior to today, and today 67 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a call option sweep that happens to be bearish, expiring in 150 day(s) on September 19, 2025. This event was a transfer of 30 contract(s) at a $390.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $27.3K, with a price of $910.0 per contract. There were 137 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option sweep that happens to be bearish, expiring in 59 day(s) on June 20, 2025. This event was a transfer of 12 contract(s) at a $135.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $2270.0 per contract. There were 1737 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 115 day(s) on August 15, 2025. This event was a transfer of 5 contract(s) at a $700.00 strike. The total cost received by the writing party (or parties) was $76.8K, with a price of $15360.0 per contract. There were 53 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with bearish sentiment. It expires in 150 day(s) on September 19, 2025. Parties traded 4 contract(s) at a $530.00 strike. The total cost received by the writing party (or parties) was $41.0K, with a price of $10250.0 per contract. There were 119 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISRG

PTCT

VSTM

9 Health Care Stocks With Whale Alerts In Today's Session

Cantor Fitzgerald analyst Carter Gould initiates coverage on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight rating and announces Price Target of $975.

Cantor Fitzgerald Initiates Coverage On Eli Lilly with Overweight Rating, Announces Price Target of $975

Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is scheduled to release its first quarter 2025 <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">earnings on 29 April</a>.
Analysts forecast adjusted earnings of 70 cents per share with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44377465/pfizer-invites-public-to-view-and-listen-to-webcast-of-april-29-conference-call-with-analysts" rel="noreferrer noopener">sales of $14.26 billion</a>.
BofA updated its earnings model for 1Q25 as analyst Tim Anderson lowered total revenue estimates by -2.1%, primarily due to updated assumptions regarding the impact of Part D on the portfolio and tweaks to Paxlovid seasonality. EPS follows, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">decreasing by -4.9%</a>.
For 2025 and 2026, BofA increased total revenue estimates slightly (&lt;1%), partly related to updated FX assumptions and smaller product-level revisions. The analyst increased EPS estimates by +1.2% and +5.3%.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
Citing a relative pharma group whose P/E multiple has recently declined due to tariff and drug pricing fears, BofA has reduced Pfizer&#8217;s price target from $29 to $26, reiterating its Neutral rating.
Pfizer&#8217;s stock is trading at about 7 times its expected 2024 earnings, which is lower than the peer average of around 11 times (excluding Eli Lilly and Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>)).
It also offers a high dividend yield of about 8%, which could help keep the stock price from falling much further. The BofA analyst notes that the long-term growth outlook is weaker than average due to upcoming patent expirations and rising competition for some of its key products.
Anderson says the focus of the earnings call will likely include:
<ul>
<li>A few months into the new administration, there is still uncertainty about how agencies like the Department of Health and Human Services (HHS) and the Centers for Medicare &amp; Medicaid Services (CMS) will operate under new leadership.
<ul>
<li>This matters for Pfizer, as around 12% of its total revenue comes from vaccine sales in the U.S. So far, the company's 2025 guidance does not factor in any potential changes to U.S. health policy.</li>
</ul>
</li>
<li>Pfizer has manufacturing facilities in Belgium, Germany, India, Ireland, Italy, Japan, and Singapore. Like many other companies, it hasn't commented yet on how possible <a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noreferrer noopener">pharmaceutical tariffs</a> might affect its profit margins or earnings per share. Analysts will likely get the best chance to ask management about this during the first-quarter 2025 earnings call.
<ul>
<li>&#8220;Our belief is that most/all companies will likely not quantify any potential impact at the moment,&#8221; Anderson writes.</li>
</ul>
</li>
<li>After the recent setback with danuglipron, the company still has an oral GLP-1 drug in early development and a GIPR blocker <a href="https://www.benzinga.com/general/biotech/25/04/44790653/pfizer-discontinues-once-daily-weight-loss-pill-over-liver-injury-in-one-patient" target="_blank" rel="noreferrer noopener">in Phase 2 trials</a>.
<ul>
<li>However, if Pfizer is serious about expanding in the obesity space, it will likely need to consider mergers, acquisitions, or other business deals to strengthen its position.</li>
</ul>
</li>
</ul>
Price Action: PFE stock is down 0.88% at $21.95 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44903362/american-express-solid-revenue-and-spending-trends-drive-analyst-optimism" target="_blank" rel="noreferrer noopener">American Express&#8217; Solid Revenue, Spending Trends Drive Analyst Optimism</a></li>
</ul>
Photo: Shutterstock

Guidance

Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline

Press Releases

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Organovo Provides Business Update

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

LillyDirect platform expands to facilitate access to Alzheimer's disease care

Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels

Kanvas Bio Publishes New Research on its Novel Spectral Imaging Platform, a Transformative Tool for Microbiome Drug Discovery and Development

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

Lilly confirms date and conference call for first-quarter 2025 financial results announcement

STAAR Surgical Announces Changes to Board of Directors

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly's Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders

Comments

Eli Lilly

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
01:01 PMApr 01, 2025	CALL	$860.00	Jun 20, 2025	51	405	400	34	1186	TRADE	BEARISH
10:45 AMApr 01, 2025	PUT	$820.00	Mar 20, 2026	324	60	60	41	145	SWEEP	BULLISH
09:54 AMApr 01, 2025	CALL	$420.00	Aug 15, 2025	107	20	20	1000	2	TRADE	BULLISH
12:00 PMMar 31, 2025	PUT	$1180.00	Dec 18, 2026	597	333	20	Infinity	0	SWEEP	NEUTRAL
12:00 PMMar 31, 2025	PUT	$1180.00	Dec 19, 2025	233	133	20	Infinity	0	SWEEP	NEUTRAL
11:44 AMMar 31, 2025	PUT	$1120.00	Dec 19, 2025	233	95	20	1056	9	SWEEP	NEUTRAL
11:44 AMMar 31, 2025	PUT	$1180.00	Dec 18, 2026	597	95	20	Infinity	0	SWEEP	BULLISH
03:14 PMMar 28, 2025	CALL	$870.00	Oct 17, 2025	170	71	71	1420	5	SWEEP	BEARISH
10:50 AMMar 28, 2025	CALL	$540.00	Jul 18, 2025	79	30	26	333	9	SWEEP	BEARISH
10:47 AMMar 28, 2025	CALL	$500.00	Jun 20, 2025	51	40	20	400	10	SWEEP	BEARISH
10:47 AMMar 28, 2025	CALL	$440.00	Aug 15, 2025	107	28	28	1400	2	SWEEP	BEARISH
03:27 PMMar 27, 2025	CALL	$840.00	Dec 18, 2026	597	50	50	75	67	TRADE	BULLISH
12:26 PMMar 27, 2025	PUT	$810.00	May 16, 2025	16	604	600	228	265	TRADE	BEARISH
03:07 PMMar 26, 2025	CALL	$460.00	Jan 15, 2027	625	20	20	100	20	TRADE	BEARISH
01:06 PMMar 25, 2025	PUT	$850.00	Apr 04, 2025	-26	1040	500	1825	57	SWEEP	BEARISH